Leiomyosarcoma natural history: Difference between revisions
Nima Nasiri (talk | contribs) No edit summary |
Nima Nasiri (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Leiomyosarcoma]] most commonly metastasizes to the [[lungs]], [[liver,]] [[abdomen]], [[pelvis]], and pelvic or paraaortic lymph nodes. | [[Leiomyosarcoma]] of uterus is an agressive soft tissue tumor which is diagnosed accidentally when they remove fibroid tumor and histology analysis reveal the aggressive nature of tumor. LMS most commonly metastasizes to the [[lungs]], [[liver,]] [[abdomen]], [[pelvis]], and pelvic or paraaortic lymph nodes. Bone and brain metastases are less common sites of involvement. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary, in those that tumor spread beyond uterus and pelvic, prognosis is very poor. Overall survival rate ranges from 15% to 25% with a median survival of only 10 months. Prognosis depends mainly on the age of the patient, race, FIGO stage, mitotic index and hormonal receptor expression in the tumor. | ||
==Natural History== | ==Natural History== | ||
Revision as of 14:59, 6 March 2019
|
Leiomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leiomyosarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Leiomyosarcoma natural history |
|
Risk calculators and risk factors for Leiomyosarcoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
Leiomyosarcoma of uterus is an agressive soft tissue tumor which is diagnosed accidentally when they remove fibroid tumor and histology analysis reveal the aggressive nature of tumor. LMS most commonly metastasizes to the lungs, liver, abdomen, pelvis, and pelvic or paraaortic lymph nodes. Bone and brain metastases are less common sites of involvement. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary, in those that tumor spread beyond uterus and pelvic, prognosis is very poor. Overall survival rate ranges from 15% to 25% with a median survival of only 10 months. Prognosis depends mainly on the age of the patient, race, FIGO stage, mitotic index and hormonal receptor expression in the tumor.
Natural History
Most Leiomyosarcoma are diagnosed incidentally at an advanced stage. A leiomyosarcoma, especially in the early stages, may not be associated with any obvious symptoms (asymptomatic).The majority of patients with leiomyosarcoma remain asymptomatic for decades. General symptoms associated with cancer may occur including fatigue, fever, weight loss, a general feeling of ill health (malaise), and nausea and vomiting. This heterogeneous group of mesenchymal neoplasms are relatively rare and may arise in soft tissue, skin or various organs, and show a broad range of differentiation, such as smooth muscle (leiomyosarcoma), adipocyte (liposarcoma), striated muscle (rhabdomyosarcoma), endothelium (angiosarcoma) or fibroblast (e.g., dermatofibrosarcoma)
Complications
They are invariably aggressive that may metastasize to other areas of the body such as the lungs or liver, potentially causing life-threatening complications. Leiomyosarcoma has a high risk of recurring of about 53% to 71% after treatment, if not diagnosed early.[1]
Prognosis
The prognosis of leiomyosarcoma is poor and it depends on varying factors including site of tumor, size, and type, as well as the extent of tumor spread. Some patients with low grade tumors or with tumors that have not spread beyond Stage I have had excellent . There are numerous long term survivors from this group. In general, high-grade tumors that have spread widely throughout the body have less favorable survival rates.
- Tumor location
- Tumor type/Grade[2]
- DNA content
- Hormonal receptor status
- cellular division and mitotic rate
- local and distant extension
- Whether or not the tumor can be removed by surgery
- The patient’s general health
References
- ↑ Gadducci A (2011) Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 25 (6):783-95. DOI:10.1016/j.bpobgyn.2011.06.002 PMID: 21764643
- ↑ Giuntoli RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL et al. (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89 (3):460-9. PMID: 12798712